Indevus Acquired - Take the $$$

Tags: idev, endp
9 Jan 3:07am
Posted by ZacksResearch
0 Comments
Read original blog entry

Just two short weeks ago, we initiated coverage of Indevus Pharmaceuticals (IDEV) with a Buy rating and $6 price target. Paramount to our investment thesis was the eventual approval of Nebido in late calendar 2009.

We were encouraged by the fact that management has come to an agreement with the FDA on the re-filing of the Nebido NDA, and believed that approval will be a transformational event for Indevus. We were also bullish on the rest of the pipeline.

Endo Pharmaceuticals (ENDP) must agree, having just signed a definitive merger agreement with Indevus worth up to $7.50 per share to Indevus shareholders. We are advising clients to take the money as such, our rating is now Hold.

Read the full analyst report on IDEV




Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries